idelalisib

Known as: 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H- quinazolin-4-one, 5-Fluoro-3-phenyl-2-((S)-1-(9H-purin-6-ylamino)-propyl)-3H-quinazolin-4-one, 5-fluoro-3-phenyl-2-[(1S)-1-(3H-purin-6-ylamino)propyl]quinazolin-4(3H)-one 
An orally bioavailable, small molecule inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinase (PI3K… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2018
05020012018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Phosphoinositide 3-kinase (PI3K) activity is stimulated by diverse oncogenes and growth factor receptors, and elevated PI3K… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2015
2015
Idelalisib is a first-in-class oral inhibitor of PI3Kδ that has shown substantial activity in patients with relapsed/refractory… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
2015
2015
Idelalisib is a highly specific small-molecule phosphoinositide-3-kinase δ inhibitor that was recently approved by the Food and… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Patients with relapsed chronic lymphocytic leukemia (CLL) who have clinically significant coexisting medical… (More)
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2014
Highly Cited
2014
BACKGROUND Phosphatidylinositol-3-kinase delta (PI3Kδ) mediates B-cell receptor signaling and microenvironmental support signals… (More)
  • table 1
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
In a phase 1 trial, idelalisib (GS-1101, CAL-101), a selective inhibitor of the lipid kinase PI3Kδ, was evaluated in 54 patients… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Idelalisib, an oral inhibitor of phosphatidylinositol-3-kinase δ (PI3Kδ), was evaluated in a 48-week phase 1 study (50-350 mg… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Idelalisib (GS-1101, CAL-101), an oral inhibitor of phosphatidylinositol 3-kinase-δ, was evaluated in a phase I study in 64… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 4
Is this relevant?
2014
2014
The phosphoinositide 3-kinase (PI3K) signal transduction pathway is highly active in tumors and drives many of the hallmarks of… (More)
  • figure 1
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Phosphatidylinositol-3-kinase p110δ serves as a central integration point for signaling from cell surface receptors known to… (More)
  • figure 1
  • figure 2
Is this relevant?